Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Conferences
- AACR23
- AACR22
- AACR21
- AACR20
- AACR19
- AACR18
- AACR17
- AACR16
- AACR15
- AACR14
- AACR IO
- AAI ASGCT
- ASCO GI
- ASCO GU
- ASCO-SITC
- AACR EORTC Mol Targets
- ASCO23
- ASCO22
- ASCO21
- ASCO20
- ASCO19
- ASCO18
- ASCO17
- ASCO16
- ASCO15
- ASCO14
- ASH23
- ASH22
- ASH21
- ASH20
- ASH19
- ASH18
- ASH17
- ASH16
- ASH15
- AUA
- BMT
- CIML40
- CIMT
- EACR
- EAU
- ECCO
- EHA iCML
- ESMO23
- ESMO22
- ESMO21
- ESMO20
- ESMO19
- ESMO18
- ESMO17
- ESMO16
- ESMO14
- JPM22
- JPM20
- SABCS
- SITC 2023
- SITC 2022
- SITC 2021
- SITC 2020
- SITC 2019
- SITC 2018
- SITC 2017
- SITC 2016
- SITC 2015
- SITC 2014
Targets
- ADC
- Adenosine
- AI & ML
- Bispecifics / Trispecifics
- Cytokines
- DDR
- Epigenetics
- gamma delta T cells
- MYC
- Neoantigens
- NK Cells
- RAS
- SERDs
- STING
- TIGIT
- TLRs
About
Contact
Pricing
Immuno-Oncology
Protein Degraders
Cell Therapy
Interviews
AACR24
Premium Content
Login

Unexpected developments at SITC23

Some up and coming novel ADCs to watch out for

November 6, 2023

Terms of Use & Privacy Policy
Copyright © 2010-24 Biotech Strategy Blog

error: Content is protected !!